University of Pennsylvania

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1740-11-14

Employees: 5K

Market Cap: -

Website: http://www.upenn.edu

Clinical Trials

CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy

Phase 1

Completed

Conditions: Adult Acute Lymphoblastic Leukemia in Remission
Recurrent Grade 2 Follicular Lymphoma
Stage III Mantle Cell Lymphoma
Hematopoietic/Lymphoid Cancer
B-cell Chronic Lymphocytic Leukemia
Recurrent Adult Diffuse Large Cell Lymphoma
Recurrent Grade 3 Follicular Lymphoma
Recurrent Mantle Cell Lymphoma
Stage III Adult Diffuse Large Cell Lymphoma
Stage III Grade 1 Follicular Lymphoma

Interventions: Biological: CART-19

First Posted Date: 2009-12-10

Last Posted Date: 2023-06-22

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 26

Registration Number: NCT01029366

Locations: 🇺🇸
Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States

Desensitization With Belimumab in Sensitized Patients Awaiting Kidney Transplant

Phase 2

Terminated

Conditions: Desensitization

Interventions: Drug: Belimumab

First Posted Date: 2009-12-03

Last Posted Date: 2017-06-12

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 8

Registration Number: NCT01025193

Locations: 🇺🇸
University of Pennsyvlania Kidney Transplant Program, Philadelphia, Pennsylvania, United States

CD3/CD28 Bead Activated T-Cells Following Chemo-Immunotherapy in Patients With Chronic Lymphocytic Leukemia

Phase 1

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Biological: Infusion of CD3/CD28 stimulated T cells

First Posted Date: 2009-11-13

Last Posted Date: 2019-10-23

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 20

Registration Number: NCT01013441

Locations: 🇺🇸
Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
MD Anderson Cancer Center, University of Texas, Houston, Texas, United States

CD4-ZETA Gene Modified T Cells With and Without Exogenous Interleukin-2 (IL-2) In HIV Patients

Phase 1

Completed

Conditions: HIV-1 Infections

Interventions: Biological: T cells
Drug: HAART

First Posted Date: 2009-11-13

Last Posted Date: 2022-08-19

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 17

Registration Number: NCT01013415

Locations: 🇺🇸
Walter Reed Army Medical Center, Washington, District of Columbia, United States

Pilot Study of Text Message Reminders to Improve HIV Medication Adherence in Botswana

Not Applicable

Completed

Conditions: HIV Infections

First Posted Date: 2009-10-27

Last Posted Date: 2015-09-17

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 128

Registration Number: NCT01001741

Locations: 🇧🇼
Independence Surgery, Gaborone, Botswana

PGD2 Formation in Vascular Injury

Terminated

Conditions: Stable Angina
Acute Coronary Syndrome
Coronary Artery Disease

Interventions: Drug: 325 mg ASA
Drug: No ASA
Drug: Low dose ASA

First Posted Date: 2009-10-26

Last Posted Date: 2019-06-11

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 51

Registration Number: NCT01001260

Neural Substrates in Nicotine Withdrawal

Phase 2

Completed

Conditions: Tobacco Use Disorder

Interventions: Drug: Placebo
Drug: Tolcapone

First Posted Date: 2009-10-26

Last Posted Date: 2014-07-02

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 218

Registration Number: NCT01001520

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

Redirected High Affinity Gag-Specific Autologous T Cells for HIV Gene Therapy

Phase 1

Completed

Conditions: HIV Infections

Interventions: Biological: WT-gag-TCR modified T cells
Biological: α/6-gag-TCR modified T cells
Other: STI or Drug Holiday

First Posted Date: 2009-10-07

Last Posted Date: 2019-10-10

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 2

Registration Number: NCT00991224

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis

Phase 3

Completed

Conditions: Microscopic Polyangiitis (MPA)
Granulomatosis With Polyangiitis (Wegener's) (GPA)

Interventions: Procedure: Plasma Exchange
Other: No Plasma Exchange
Drug: Glucocorticoids [Standard Dose]
Drug: Glucocorticoids [Reduced Dose]

First Posted Date: 2009-09-30

Last Posted Date: 2020-05-26

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 704

Registration Number: NCT00987389

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸
University of North Carolina, Chapel Hill, North Carolina, United States
🇺🇸
University of Virginia, Charlottesville, Virginia, United States

and more 95 locations

Evaluation of an Algorithm to Reduce Antibiotic Prescribing for Acute Bronchitis

Not Applicable

Completed

Conditions: Acute Respiratory Tract Infection

Interventions: Behavioral: Decision Support for ARI Management

First Posted Date: 2009-09-22

Last Posted Date: 2016-11-28

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 3300

Registration Number: NCT00981994

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy